Clinical Trials Logo

Spondylarthritis clinical trials

View clinical trials related to Spondylarthritis.

Filter by:

NCT ID: NCT05881785 Active, not recruiting - Clinical trials for Axial Spondyloarthritis

Study of Efficacy and Safety of GR1501 in Patients With Radiographic Axial Spondyloarthritis

Start date: June 13, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to demonstrate the clinical efficacy of GR1501 at week 16; and to demonstrate safety and tolerability of GR1501 compared to placebo in patients with Radiographic Axial Spondyloarthritis at week 16 and long term safety up to Week 48。 The main question it aims to answer is whether GR1501 injection was superior to placebo in the proportion of subjects with ASAS20 response at week 16 in patients with Radiographic Axial Spondyloarthritis.

NCT ID: NCT05866614 Recruiting - Clinical trials for Rheumatoid Arthritis

A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps

Start date: January 13, 2023
Phase:
Study type: Observational [Patient Registry]

This is an observational, prospective cohort study to evaluate the safety of Remsima® SC in the treatment of RA, AS, PsA and Ps.

NCT ID: NCT05861128 Recruiting - Clinical trials for Ankylosing Spondylitis

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

Start date: November 10, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.

NCT ID: NCT05861102 Recruiting - Clinical trials for Ankylosing Spondylitis

Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

Start date: July 20, 2023
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Jaktinib in subjects with active Ankylosing Spondylitis(AS).

NCT ID: NCT05839925 Completed - Clinical trials for Ankylosing Spondylitis

Prevalence of Temporomandibular Joint Dysfunction in Patients With Ankylosing Spondylitis

Start date: April 1, 2022
Phase:
Study type: Observational

This study included 113 patients diagnosed with ankylosing spondylitis and 110 healthy volunteers. Participants in both groups were evaluated using the 'Diagnostic Criteria for Temporomandibular Disorders (DC/TMD)' diagnostic criteria. In addition, the relationship between temporomandibular joint dysfunction and disease activity was investigated in patients with ankylosing spondylitis.

NCT ID: NCT05835518 Recruiting - Clinical trials for Rheumatoid Arthritis

An Observational, Prospective Study to Assess the Efficacy and Safety of Adalloce in Patients With RA and AS

Start date: January 26, 2023
Phase:
Study type: Observational

This Study is to Assess the Efficacy and Safety of Adalloce in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis, An Observational, Prospective Study

NCT ID: NCT05814939 Recruiting - Clinical trials for Active Ankylosing Spondylitis

Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

Start date: April 26, 2023
Phase: Phase 2
Study type: Interventional

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.

NCT ID: NCT05812157 Recruiting - Clinical trials for Axial Spondyloarthritis

Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17

RESPOND-IL17
Start date: October 2, 2023
Phase: N/A
Study type: Interventional

Fiber is the main source of energy for colonic bacteria and its consumption favorably modifies the composition of the microbiota in only a few days. Their fermentation in the colon releases short-chain fatty acids (SCFAs). Clostridiales contain many strains producing SCFAs. These SCFAs can restore the intestinal barrier and promote certain anti-inflammatory cells, including regulatory T cells (Tregs), which are essential to the mechanisms in tolerance of the self. Fibers could therefore correct the intestinal abnormalities present in patients with axial spondyloarthritis (AxSpA) and aggravated by anti-IL-17 drugs and thus improve the therapeutic response to these treatments. The hypothesis is that dietary fiber will correct the dysbiosis in AxSpA patients and increase the release of SCFAs, which favorably modulate the immune response and improve AxSpA.

NCT ID: NCT05792358 Enrolling by invitation - Clinical trials for Ankylosing Spondylitis

Wet Cupping Therapy in Ankylosing Spondylitis

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

This study evaluates the efficacy of wet cupping therapy in patients with ankylosing spondylitis.Wet cupping therapy will be applied to half of the patients plus routine pharmaceutical treatment while the other half will receive only pharmaceutics

NCT ID: NCT05785611 Active, not recruiting - Clinical trials for Axial Spondyloarthritis

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

OLINGUITO
Start date: April 5, 2023
Phase: Phase 3
Study type: Interventional

This study is comparing 200 milligrams (mg) of filgotinib a day with a placebo to see if filgotinib helps to treat Axial Spondyloarthritis (axSpA) and is safe to use. The study will also be comparing 200 mg with 100 mg filgotinib a day to see if the lower dose also helps to treat axSpA.